e-therapeutics plc Stock price

Equities

ETX

GB00B2823H99

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:15 2024-03-28 pm EDT 5-day change 1st Jan Change
11 GBX -1.35% Intraday chart for e-therapeutics plc -10.57% +33.50%
Sales 2022 0.48 Sales 2023 0.48 Capitalization 93.73M
Net income 2022 -8M Net income 2023 -8M EV / Sales 2022 306,956,621 x
Net cash position 2022 25.96M Net cash position 2023 31.39M EV / Sales 2023 131,228,741 x
P/E ratio 2022
-20.3 x
P/E ratio 2023
-10.5 x
Employees 34
Yield 2022 *
-
Yield 2023
-
Free-Float 40.56%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.35%
1 week-10.57%
Current month-19.85%
1 month-21.43%
3 months+29.41%
6 months-16.82%
Current year+33.50%
More quotes
1 week
10.65
Extreme 10.65
12.90
1 month
10.65
Extreme 10.65
14.30
Current year
8.02
Extreme 8.02
18.72
1 year
8.00
Extreme 8
24.00
3 years
8.00
Extreme 8
49.50
5 years
1.40
Extreme 1.4
49.50
10 years
1.40
Extreme 1.4
49.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 20-01-31
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 82 15-10-27
Director/Board Member 68 20-02-10
Chief Executive Officer 53 20-01-31
More insiders
Date Price Change Volume
24-03-28 11 -1.35% 169 497
24-03-27 11.15 -4.90% 252,011
24-03-26 11.72 -3.30% 98,333
24-03-25 12.12 -0.82% 749,944
24-03-22 12.22 -0.81% 200,944

Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT

More quotes
e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.
More about the company
  1. Stock
  2. Equities
  3. Stock e-therapeutics plc - London S.E.